Figure 5.

Biodistribution and pharmacokinetic profile of the ¹¹¹In-EGF-LP liposomal formulation in vivo in mice bearing subcutaneous MDA-MB-468 tumours. (A) Biodistribution of ¹¹¹In-EGF-LP in mice bearing MDA-MB-468 xenografts expressed as percentage of injected dose per organ (%ID/organ) (n = 4, standard deviation shown). (B) Ratios of tumour to blood and muscle. (C) Autoradiography showing the distribution of ¹¹¹In in one slice of the tumour (representative image). (D) MRI section of an MDA-MB-468 tumour and (E) MRI signal enhancement obtained after injection of a MRI contrast agent to mice bearing MDA-MB-468 tumour. The curve for muscle in white is shown for comparison. (F) Blood lifetime of ¹¹¹In-EGF-LP obtained by SPECT with or without pre-treatment of mice with clodronate liposomes (n = 3, standard deviation shown).